These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 35608132)

  • 1. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
    Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Zhang S; Xu F; Lei S; Wang Y
    Cancer Med; 2023 Jan; 12(1):335-344. PubMed ID: 35608132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.
    Wang H; Xu Y; Lin J; Huang Y
    Cancer Control; 2024; 31():10732748241262190. PubMed ID: 38857163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
    Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
    Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
    Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors.
    Girard N; Minchom A; Ou SI; Gadgeel SM; Trigo J; Viteri S; Bauml JM; Londhe A; Mahadevia P; Bazhenova L
    Clin Lung Cancer; 2022 Nov; 23(7):571-577. PubMed ID: 36085282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Sa H; Shi Y; Ding C; Ma K
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7729-7742. PubMed ID: 37004599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
    Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
    Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion.
    Zheng Y; Fu Y; Chen Y; Li Q; Liu T; Ding Z
    Curr Oncol; 2023 Nov; 30(11):9929-9939. PubMed ID: 37999141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions.
    Liao YT; Wang LC; Sun RL; Yeh YC; Huang HC; Shen CI; Tseng YH; Hsiao TH; Chao HS; Luo YH; Chen YM; Chiang CL
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10365-10376. PubMed ID: 37277579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
    Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
    Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
    Shah MP; Aredo JV; Padda SK; Ramchandran KJ; Wakelee HA; Das MS; Neal JW
    Clin Lung Cancer; 2022 Mar; 23(2):e148-e153. PubMed ID: 34391686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab and chemotherapy in non-small cell lung cancer with EGFR ex20ins mutation: A case report.
    Zhang M; Nie L; Cheng Y
    Thorac Cancer; 2021 Oct; 12(20):2803-2806. PubMed ID: 34382340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis.
    Zhang M; Huang Q; Yu M; Xue J; Huang M; Lu Y; Zhang Y
    Transl Lung Cancer Res; 2023 Apr; 12(4):797-807. PubMed ID: 37197626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with
    Choudhury NJ; Schoenfeld AJ; Flynn J; Falcon CJ; Rizvi H; Rudin CM; Kris MG; Arcila ME; Heller G; Yu HA; Ladanyi M; Riely GJ
    Clin Cancer Res; 2021 May; 27(10):2920-2927. PubMed ID: 33685865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Clinical Outcomes for Patients with
    Li K; Bosdet I; Yip S; Ho C; Laskin J; Melosky B; Wang Y; Sun S
    Curr Oncol; 2023 Jul; 30(8):7099-7111. PubMed ID: 37622996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
    Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
    Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.
    Tu HY; Yin K; Zhao X; Ke EE; Wu SP; Li YS; Zheng MM; Liu SM; Xu CR; Sun YL; Lin JX; Bai XY; Zhang YC; Zhou Q; Yang JJ; Zhong WZ; Wang BC; Zhang XC; Zhu D; Yang L; Ou Q; Wu YL
    Mol Oncol; 2023 Aug; 17(8):1581-1594. PubMed ID: 37078460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with
    Metro G; Baglivo S; Bellezza G; Mandarano M; Gili A; Marchetti G; Toraldo M; Molica C; Reda MS; Tofanetti FR; Siggillino A; Prosperi E; Giglietti A; Di Girolamo B; Garaffa M; Marasciulo F; Minotti V; Gunnellini M; Guida A; Sassi M; Sidoni A; Roila F; Ludovini V
    Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33946594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.